More on AEMD
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Net loss | |
| Depreciation and amortization | 20.61K |
| Amortization of deferred consulting fees | |
| Loss on settlement of accrued interest and damages | |
| Gain on sale of property and equipment | |
| Gain on settlement of debt | |
| Loss on settlement of accrued legal liabilities | |
| Stock based compensation | 1.57M |
| Legal fees paid through the issuance of convertible debt | |
| Fair market value of common shares donated to research institute | |
| Loss on debt extinguishment | |
| Fair market value of warrants issued in connection with accounts payable and debt | |
| Fair market value of conditional warrants that subsequently were issued | |
| Non cash interest expense | |
| Liquidated damages | |
| Fair market value of common stock, warrants and options issued for services | |
| Change in fair value of derivative liabilities | |
| Issuance of note in convertible note termination | |
| Patent license fees paid in stock | |
| Amortization of debt discount and deferred financing costs | 46.64K |
| Impairment of intangible assets | |
| Deferred compensation forgiven | |
| Prepaid expenses and other current assets | -12.51K |
| Interest receivable | |
| Accounts payable and other current liabilities | 125.84K |
| Due to related parties | -86.75K |
| Net cash used in operating activities | |
| Purchases of property and equipment | -2.96K |
| Additions to patents and patents pending | |
| Proceeds from the sale of property and equipment | |
| Cash of acquired company | |
| Net cash used in investing activities | |
| Proceeds from the issuance of notes payable | |
| Principal repayments of notes payable | |
| Net proceeds from the issuance of convertible notes payable | |
| Proceeds from the issuance of common stock | 266.61K |
| Proceeds from collection of secured notes receivable | |
| Professional fees related to registration statement | |
| Net cash provided by financing activities | |
| Net (decrease) increase in cash | -1.57M |
| Cash at beginning of period | 2.12M |
| Cash at end of period | 556.35K |
| Interest | |
| Income taxes | |
| Derivative liabilities recorded in connection with embedded conversion feature of convertible notes and/or warrants | |
| Debt and accrued interest converted to common stock | |
| Deferred financing costs recorded in connection with debt restructuring | |
| Debt discount recorded in connection with beneficial conversion feature of convertible notes and related warrants | |
| Issuance of convertible notes in settlement of accrued legal fees | |
| Reclassification of accounts payable to notes payable | |
| Reclassification of warrant derivative liability into equity | |
| Additional convertible debt issued in debt restructuring | |
| Stock option exercise by director for accrued expenses | |
| Issuance of common stock, warrants and options in settlement of accrued expenses and due to related parties | |
| Issuance of common stock in connection with acquisition of patent pending and with license agreements | |
| Net assets of entities acquired in exchange for equity securities | |
| Debt placement fees paid by issuance of warrants | |
| Common stock issued for prepaid expenses | |
Entities mentioned with AEMD
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S1 | View Related Stories »
- H.C. Wainwright | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
